| abstract |
The present invention provides a pyrazolopyridine derivative having a GLP-1 receptor agonist activity, and a preventive or therapeutic agent for non-insulin-dependent diabetes (type 2 diabetes) or obesity containing the derivative as an active ingredient. A compound of the following formula (I): (Wherein X represents —N═ or —CR a ═, Y represents —C (═O) —, —S (═O) 2 —, etc., and R a represents a hydrogen atom, a halogen atom, or the like. , Q 1 is C 6-10 aryl or 5-10 membered heteroaryl, Q 2 is 3-12 membered heterocyclyl or 5-10 membered heteroaryl, R 1 , R 2 , and R 3 are Each independently H or alkyl, R 4 , R 5 , and R 6 each independently H, halogen or alkyl, R 7 and R 8 each independently H or alkyl, R 9 Represents tetrazole, etc., Z 1 represents imidazole, Z 2 represents alkyl, cycloalkyl, etc., n 1 represents an integer of 0 to 3, and n 2 represents an integer of 0 to 5.) [Selection figure] None |